Progyny (PGNY) Competitors

Guardant Health (NASDAQ:GH) and Progyny (NASDAQ:PGNY) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, earnings, risk, media sentiment, valuation, analyst recommendations and institutional ownership.

Does the media favor GH or PGNY?

In the previous week, Progyny had 4 more articles in the media than Guardant Health. MarketBeat recorded 16 mentions for Progyny and 12 mentions for Guardant Health. Guardant Health's average media sentiment score of 1.01 beat Progyny's score of 0.95 indicating that Guardant Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Guardant Health	6 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Progyny	4 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has preferable valuation & earnings, GH or PGNY?

Progyny has higher revenue and earnings than Guardant Health. Guardant Health is trading at a lower price-to-earnings ratio than Progyny, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Guardant Health	$774.00M	7.65	-$436.37M	-$3.39	-14.10
Progyny	$1.21B	1.63	$54.34M	$0.57	40.39

Do insiders and institutionals hold more shares of GH or PGNY?

92.6% of Guardant Health shares are held by institutional investors. Comparatively, 94.9% of Progyny shares are held by institutional investors. 6.1% of Guardant Health shares are held by insiders. Comparatively, 9.4% of Progyny shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Do analysts prefer GH or PGNY?

Guardant Health currently has a consensus price target of $53.76, indicating a potential upside of 12.45%. Progyny has a consensus price target of $24.09, indicating a potential upside of 4.65%. Given Guardant Health's stronger consensus rating and higher possible upside, equities research analysts plainly believe Guardant Health is more favorable than Progyny.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Guardant Health	0 Sell rating(s)	0 Hold rating(s)	21 Buy rating(s)	1 Strong Buy rating(s)	3.05
Progyny	0 Sell rating(s)	5 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.67

Which has more volatility & risk, GH or PGNY?

Guardant Health has a beta of 1.44, meaning that its stock price is 44% more volatile than the S&P 500. Comparatively, Progyny has a beta of 1.31, meaning that its stock price is 31% more volatile than the S&P 500.

Is GH or PGNY more profitable?

Progyny has a net margin of 4.33% compared to Guardant Health's net margin of -53.82%. Progyny's return on equity of 10.90% beat Guardant Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Guardant Health	-53.82%	N/A	-26.77%
Progyny	4.33%	10.90%	7.20%

Summary

Progyny beats Guardant Health on 10 of the 16 factors compared between the two stocks.